Navigation Links
ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Date:9/4/2012

BARCELONA, Spain, September 4, 2012 /PRNewswire/ --

  • E-52862 is a potent, highly selective NCE with a novel mechanism of action (MOA; Sigma 1 Receptor (S1R) antagonism) currently being evaluated for the treatment of pain
  • Key data are outlined from three Phase I studies involving 175 male and female human subjects
  • These studies demonstrate a favourable safety, tolerability, pharmacokinetic and pharmacodynamic profile for E-52862
  • Phase II clinical trials evaluating E-52862 are ongoing

ESTEVE announces the recent publication of data from the Phase I clinical trial programme of a novel, highly potent and selective, once-daily, S1RA E-52862, developed by the ESTEVE R&D team, in the British Journal of Clinical Pharmacology[1].

     (Logo: http://photos.prnewswire.com/prnh/20120904/554843)

Mariano Sust, M.D., corresponding author, stated that "E-52862 represents a NCE with a novel, unprecedented mechanism of action for pain of different aetiologies.  We are very encouraged by these results and look forward to future findings from the E-52862 clinical trial programme in due course."

To fully validate the safety and tolerability of E-52862, ESTEVE performed a rigorous phase I programme. This publication reports results from three, Phase I studies involving 175 human subjects. E-52862 demonstrated a favourable safety and tolerability profile across a robust panel of assessments including adverse event recording following questioning and spontaneous reporting; physical examinations; vital signs measurements; laboratory safety tests (haematology, blood coagulation, biochemistry, urinalysis); multiple psychometric tests; computerized cognitive evaluations (including assessment of executive function, working memory and learning, reaction time and psychomotor functions); and thorough cardiac monitoring
'/>"/>

SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ESTEVE Communicates its R&D Through a New Interactive Platform
2. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
3. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
4. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
5. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
6. Clinical Site Services, Industry Leader in Patient Enrollment Solutions, Announces New Website
7. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
8. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
9. Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology
10. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 This webinar ... on nonclinical and clinical safety assessment in biosimilars. ... guide a path for biosimilar drug development, however ... of biosimilarity with regards to quality, safety and ... of biosimilar drug development and registration, development strategies ...
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 ... an enhancement to its Online Web Portal for Life ... now have the ability to specify the subject matter ... nearly 50 life science sub-domains. This will help reduce ... and scientific fields, and decrease the likelihood of error. ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 ... – 11 p.m. , Location: Warrington Country Club, 1360 ... Hepatitis B Foundation, the only national nonprofit organization solely ... improving the quality of life for those affected worldwide, ... 11 at Warrington Country Club in Warrington, Pa. ...
(Date:1/14/2014)... York, NY (PRWEB) January 14, 2014 ... initiated coverage of Alliqua, Inc. (OTCQB: ALQA). Alliqua ... and marketing proprietary products to serve the wound ... , In late 2012, Alliqua was restructured ... launched the company’s new strategy to become a ...
Breaking Biology Technology:Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Scheduled for Thursday, May 7, 2009 at 5:30 p.m. Eastern ... ALXA ) announced today that it will release ... on Thursday, May 7, 2009, following the close of the ... conference call to discuss the financial results and other clinical ...
... at 5:00 p.m. ET (22:00 CET)NOVATO, Calif., April 30 , ... ... BioMarin Revenue $74.0 ... $71.9 ...
... Bio, Maxis IT and Rescentris recognized for their innovation across the ... ... Boston (PRWEB) April 30, 2009 -- CHI,s Bio-IT World Conference ... named Best of Show Awards winners at a ceremony held Tuesday, ...
Cached Biology Technology:Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009 2Alexza to Announce 2009 First Quarter Financial Results and Update Its Clinical Pipeline Status on Thursday, May 7, 2009 3BioMarin Announces First Quarter 2009 Financial Results 2BioMarin Announces First Quarter 2009 Financial Results 3BioMarin Announces First Quarter 2009 Financial Results 4BioMarin Announces First Quarter 2009 Financial Results 5BioMarin Announces First Quarter 2009 Financial Results 6BioMarin Announces First Quarter 2009 Financial Results 7BioMarin Announces First Quarter 2009 Financial Results 8BioMarin Announces First Quarter 2009 Financial Results 9BioMarin Announces First Quarter 2009 Financial Results 10BioMarin Announces First Quarter 2009 Financial Results 11BioMarin Announces First Quarter 2009 Financial Results 12BioMarin Announces First Quarter 2009 Financial Results 13BioMarin Announces First Quarter 2009 Financial Results 14BioMarin Announces First Quarter 2009 Financial Results 15BioMarin Announces First Quarter 2009 Financial Results 16Best of Show Awards Winners Named at Bio-IT World Conference & Expo 2Best of Show Awards Winners Named at Bio-IT World Conference & Expo 3Best of Show Awards Winners Named at Bio-IT World Conference & Expo 4Best of Show Awards Winners Named at Bio-IT World Conference & Expo 5
(Date:4/15/2014)... have found a less invasive way to extract ... study how the mouth,s natural defenses ward off ... immune cells (white blood cells known as "leukocytes") ... mouthor reject foreign tissues, such as in failed ... and preventing such health issues as oral cancers, ...
(Date:4/15/2014)... in the world for which no pharmaceutical treatment exists. ... by mosquitoes in the tropics, as well as a ... and is easily spread by the hands and can ... , Researchers at Aalto University and the University of ... prevent the spread of one type of virus into ...
(Date:4/15/2014)... April 15, 2014 New research, partially funded by ... Federation, shows that consumers can improve their diets simply ... their daily meals. , In a ... and Nutrition Sciences , lead author Theresa Nicklas, DrPH, ... and Nutrition Examination Survey datasets from 2005-2010 and evaluated ...
Breaking Biology News(10 mins):New method isolates immune cells for researchers to study how they ward off oral diseases 2Nanocrystalline cellulose modified into an efficient viral inhibitor 2Eating rice boosts diet quality, reduces body weight and improves markers for health 2Eating rice boosts diet quality, reduces body weight and improves markers for health 3
... added to the threatened species list nearly three years ago ... a warming climate. , But it appears the Arctic icons ... study published in this week,s issue of the journal ... no "tipping point" that would result in unstoppable loss of ...
... appearing in the January Journal of Lipid Research ... in any significant amount in multiple sclerosis patients, contradicting ... cholesterol metabolites were associated with MS and could be ... are somewhat controversial in science; while some laboratory experiments ...
... The virus that causes AIDS is chameleon-like in its ... mutates into forms that can evade even the best ... change as they reproduce is key to developing better ... Journal of Biological Chemistry and Nature Structural & ...
Cached Biology News:Polar bears: On thin ice? Extinction can be averted, scientists say 2Polar bears: On thin ice? Extinction can be averted, scientists say 3Link between cholesterol compound and multiple sclerosis unlikely, researchers say 2New discoveries make it harder for HIV to hide from drugs 2
Mouse polyclonal antibody raised against a partial recombinant WRB. NCBI Entrez Gene ID = 7485...
...
Mouse monoclonal to Casein Kinase 2 beta ( Abpromise for all tested applications). entrezGeneID: 1460 SwissProtID: P13862...
Mouse monoclonal antibody raised against a partial recombinant FAAH. NCBI Entrez Gene ID = FAAH...
Biology Products: